Statin randomized trials reduce major vascular events by about a fifth per 1 mmol/L reduction in LDL cholesterol
3 events · 1 assessment · 1 decision
Structured and assessed
First pass (structure_and_assess). Left the claim atomic: it is a near-verbatim restatement of the CTT Collaboration's headline meta-analytic result, and any candidate subclaim would turn on the same considerations (duplication), so decomposition was not warranted per §2/§6. Verified against primary sources via web search: CTT 2010 (26 trials, ~170k participants) RR 0.78 per 1 mmol/L LDL reduction for major vascular events; CTT 2012 low-risk analysis RR 0.79; both ~21-22% ("about one fifth"), matching the CTT's own summary language. Set importance 0.4, contestation 0.2: high consequence (cornerstone of CV prevention guidelines) but settled among experts; skeptic critiques target absolute benefit/generalization, not the pooled proportional relationship. Assessed verified, confidence 0.93, credence 0.95, marginal_yield 0.05. Parent claim (proportional LDL-lowering benefit) is already verified and consistent; no dependents below need notification.
Assessed Verified
verdict confidence 0.93 · credence 0.95
Large individual-participant meta-analyses of statin randomized trials find that each 1.0 mmol/L reduction in LDL cholesterol reduces the annual rate of major vascular events by roughly one fifth. The Cholesterol Treatment Trialists' (CTT) Collaboration, pooling data from more than 170,000 participants across 26 trials, reported a rate ratio of about 0.78 per 1 mmol/L LDL reduction, and its later analysis of trials in lower-risk participants reported a rate ratio of about 0.79; both correspond to a proportional reduction of roughly 21 to 22 percent, which the collaboration itself summarizes as "about one fifth." The effect is largely independent of baseline LDL level, age, sex, and prior vascular disease, and more intensive lowering produces proportionally larger reductions. The main qualification concerns interpretation rather than the figure: the proportional relationship is a meta-analytic average, and in low-risk primary prevention the same proportional reduction translates into a small absolute benefit. Statin-skeptic commentators dispute the size of the real-world benefit and point to variability between individual trials, but these criticisms bear on absolute benefit and generalization rather than on the existence and magnitude of the pooled per-unit relationship, which the individual-participant data support robustly.
Claim entered the graph